Aradhye Shreeram Insider Trades

Insider Trading History

Track insider trading activity for Aradhye Shreeram. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $0 0 shares
Last Trade
Dec 28, 2021 Sale (Tender)Reported as Tender on SEC Form 4.
$267k 6,973 shares
$38.25
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $0 0 shares
Last Trade
Dec 28, 2021 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$7.04M 184,283 shares
$38.22
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $298k 7,806 shares
Last Trade
Dec 15, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$108k 2,837 shares
$38.05
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $267k 6,973 shares
Last Trade
Dec 15, 2021 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$31.7k 833 shares
$38.05
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $325k 8,513 shares
Last Trade
Dec 15, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$108k 2,837 shares
$38.05
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $190k 4,969 shares
Last Trade
Sep 17, 2021 Sale (Open Market)Shares sold on the open market or in a private sale.
$44.1k 2,056 shares
$21.47
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $268k 7,025 shares
Last Trade
Sep 15, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$149k 7,025 shares
$21.21
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $805k 21,075 shares
Last Trade
Sep 15, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$149k 7,025 shares
$21.21
$38.22
Axcella Health
Axcella Health AXLA
Director
Holding Value $91.6k 20,000 shares
Last Trade
May 20, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$64.8k 20,000 shares
$3.24
$4.58
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $1.95M 51,070 shares
Last Trade
Jan 12, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.5M 62,420 shares
$24.05
$38.22
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals DRNA
EVP & Chief Medical Officer
Holding Value $4.77M 124,700 shares
Last Trade
Oct 01, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.86M 152,800 shares
$18.69
$38.22
Axcella Health
Axcella Health AXLA
Director
Holding Value $101k 22,000 shares
Last Trade
Sep 01, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$108k 22,000 shares
$4.89
$4.58
Axcella Health
Axcella Health AXLA
EVP & Chief Developmnt Officer
Holding Value $306k 66,801 shares
Last Trade
Dec 18, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$412k 121,301 shares
$3.40
$4.58
Axcella Health
Axcella Health AXLA
EVP &chief Development Officer
Holding Value $0 0 shares
Last Trade
May 22, 2019 Sale
$3.49M 244,299 shares
$14.28
$4.58

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up